A common therapeutic approach to SARS-CoV-2 complications (5) and type 2 diabetes with IL-1 blockade agents (44) can strengthen the suggestion of the association of type 2 diabetes and COVID-19 complications. The gene discussed is IL1A; the disease is type 2 diabetes mellitus.